257 related articles for article (PubMed ID: 24840813)
1. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Machens A; Dralle H
J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
[TBL] [Abstract][Full Text] [Related]
3. Can procalcitonin be useful for medullary thyroid cancer?
Kaczka K; Mikosiński S; Fendler W; Jałocha-Kaczka A; Pomorski L
Endokrynol Pol; 2010; 61(5):430-6. PubMed ID: 21049453
[TBL] [Abstract][Full Text] [Related]
4. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer.
Walter MA; Meier C; Radimerski T; Iten F; Kränzlin M; Müller-Brand J; de Groot JW; Kema IP; Links TP; Müller B
Cancer; 2010 Jan; 116(1):31-40. PubMed ID: 19890958
[TBL] [Abstract][Full Text] [Related]
5. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B
Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502
[No Abstract] [Full Text] [Related]
6. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
Machens A; Hauptmann S; Dralle H
J Clin Endocrinol Metab; 2008 Jun; 93(6):2234-8. PubMed ID: 18364379
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection.
Kaczka K; Mikosiński S; Fendler W; Celnik A; Pomorski L
Adv Clin Exp Med; 2012; 21(2):169-78. PubMed ID: 23214280
[TBL] [Abstract][Full Text] [Related]
8. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Scollo C; Baudin E; Travagli JP; Caillou B; Bellon N; Leboulleux S; Schlumberger M
J Clin Endocrinol Metab; 2003 May; 88(5):2070-5. PubMed ID: 12727956
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules.
Giovanella L; Verburg FA; Imperiali M; Valabrega S; Trimboli P; Ceriani L
Clin Chem Lab Med; 2013 Jul; 51(7):1477-81. PubMed ID: 23314540
[TBL] [Abstract][Full Text] [Related]
10. Negative predictive value of procalcitonin in medullary thyroid carcinoma.
Lim SK; Guéchot J; Vaubourdolle M
Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393
[TBL] [Abstract][Full Text] [Related]
11. Benefit-risk balance of reoperation for persistent medullary thyroid cancer.
Machens A; Dralle H
Ann Surg; 2013 Apr; 257(4):751-7. PubMed ID: 23023200
[TBL] [Abstract][Full Text] [Related]
12. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
13. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
16. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
Torresan F; Mian C; Cavedon E; Iacobone M
Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.
Algeciras-Schimnich A; Preissner CM; Theobald JP; Finseth MS; Grebe SK
J Clin Endocrinol Metab; 2009 Mar; 94(3):861-8. PubMed ID: 19088163
[TBL] [Abstract][Full Text] [Related]
18. Prediction of lateral neck lymph node metastasis according to preoperative calcitonin level and tumor size for medullary thyroid carcinoma.
Bae SY; Jung SP; Choe JH; Kim JS; Kim JH
Kaohsiung J Med Sci; 2019 Dec; 35(12):772-777. PubMed ID: 31483088
[TBL] [Abstract][Full Text] [Related]
19. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review.
Trimboli P; Seregni E; Treglia G; Alevizaki M; Giovanella L
Endocr Relat Cancer; 2015 Jun; 22(3):R157-64. PubMed ID: 25934688
[TBL] [Abstract][Full Text] [Related]
20. CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA.
Filimon S; Payne RJ; Black MJ; Hier MP; Mlynarek AM; Forest VI; Tamilia M
Endocr Pract; 2018 May; 24(5):460-467. PubMed ID: 29847167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
